You are here

Chewable Compound Reduces Post-Meal Blood Glucose in Diabetes Patients

Carbohydrate-based drug completes phase II trial (September 4)

Positive results have been reported from a phase II study that evaluated the safety and efficacy of PAZ320 (Boston Therapeutics), a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. The study was published in Endocrine Practice.

PAZ320 was evaluated in 24 patients aged 18 to 75 years with type 2 diabetes, a body mass index (BMI) of 25 to 40 kg/m2, and hemoglobin A1c (HbA1c) of ≤ 9%. HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months.

Forty-five percent of patients responded with a 40% reduction in post-meal glucose in the blood compared with baseline in a dose-dependent manner. In addition, the drug appeared to work regardless of concurrent diabetes medications.

There was no severe hypoglycemia, and gastrointestinal side effects were mild.

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. The drug is taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

Source: Boston Therapeutics; September 4, 2013.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs